HDAC1-Dependent Repression of Markers of Hepatocytes and P21 Is Involved in Development of Pediatric Liver Cancer
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Jul 2021 · 1 min read
In brief
In brief
This study identifies HDAC1-mediated epigenetic mechanisms driving hepatocyte dedifferentiation in aggressive hepatoblastoma, revealing that oncogenic C/EBPα and Sp5 complexes repress hepatocyte markers and p21. Patient-derived xenograft models demonstrate that HDAC1 inhibition restores hepatocyte differentiation markers, suggesting a therapeutic target for pediatric liver cancer.
Written by the GCMD Library team from the article.
Statements in this article
Epigenetic regulation of gene expression plays a critical role in the development of liver cancer.
A significant portion of hepatoblastoma patients have increased levels of oncogenic de-phosphorylated-S190-C/EBPα, Sp5, and HDAC1 compared with amounts of these proteins in adjacent regions.
The oncogenic de-phosphorylated-S190-C/EBPα is created in aggressive hepatoblastoma by protein phosphatase 2A, which is increased within the nucleus and dephosphorylates C/EBPα at Ser190.
C/EBPα-HDAC1 and Sp5-HDAC1 complexes are abundant in hepatocytes which dedifferentiate into cancer cells.